Ionis Pharmaceuticals has earned a $5 million milestone payment from Biogen associated with the validation of an undisclosed target to treat an undisclosed neurological disorder under the companies’ strategic collaboration. For this newest target, Ionis will continue to evaluate the target with the goal of advancing the program into development. “Our strategic collaboration with Biogen is very successful. Our most advanced program, nusinersen, is currently in Phase III studies, and we h...